Small Cell Lung Cancer: Optimism Through Immunotherapeutic Approaches

Program Overview

In this interactive panel discussion, oncology experts and a patient with small cell lung cancer (SCLC) discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Credit Expired

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with small cell lung cancer (SCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
Incorporate immunotherapy into the management of patients with SCLC, where appropriate
Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Faculty

Hossein Borghaei, DO, MS (Chair)

Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair, Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Taofeek K. Owonikoko, MD, PhD, MSCR

Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director, Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA